sorafenib has been researched along with cp 547632 in 6 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cp 547632) | Trials (cp 547632) | Recent Studies (post-2010) (cp 547632) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 19 | 1 | 13 |
| Protein | Taxonomy | sorafenib (IC50) | cp 547632 (IC50) |
|---|---|---|---|
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0093 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.0715 | |
| Angiopoietin-1 receptor | Homo sapiens (human) | 0.319 | |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | 0.237 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Engel, J; Grütter, C; Nguyen, HD; Phan, T; Rauh, D; Richters, A; Simard, JR | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
6 other study(ies) available for sorafenib and cp 547632
| Article | Year |
|---|---|
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin | 2007 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Identification of type II and III DDR2 inhibitors.
Topics: Discoidin Domain Receptors; Drug Design; Fluorescence; High-Throughput Screening Assays; Ligands; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structure-Activity Relationship | 2014 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |